Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 5/20 | 0.32 |
| ▸ | DRD2 | P14416 | 5/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.30 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8275918 | 0.85 | NAMPT (0.41) | HTR1ADRD2NAMPTDPP8BDKRB1 | |
| SCHEMBL8213511 | 0.85 | ADAM17 (0.43) | PRMT5SMYD3HTR1ADRD2NAMPT | |
| SCHEMBL8216981 | 0.84 | MEN1 (0.38) | PRMT5HTR1ADRD2NAMPTDPP8 | |
| SCHEMBL8223637 | 0.82 | NAMPT (0.39) | PRMT5NAMPTNOTUMDPP8DPP7 | |
| SCHEMBL8213997 | 0.81 | NAMPT (0.37) | PRMT5NAMPT | |
| SCHEMBL8273738 | 0.72 | ADAM17 (0.45) | HTR1ADRD2NAMPT | |
| SCHEMBL8275985 | 0.71 | MEN1 (0.41) | DRD2NAMPT | |
| SCHEMBL8221036 | 0.70 | NAMPT (0.46) | NAMPTNOTUMDPP8DPP7HDAC8 | |
| SCHEMBL8274845 | 0.70 | ADAM17 (0.44) | HTR1ADRD2NAMPT | |
| SCHEMBL8415324 | 0.69 | ADAM17 (0.47) | DRD2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039467-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100145048-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| US-7652020-B2 | novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction | SCHERING CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | PRMT5 4133/4885SMYD3 1776/4885HTR1A 4466/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | PRMT5 3853/4885SMYD3 2307/4885HTR1A 4159/4885 |
| US-20100145048-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, MMP12, MMP8 | PRMT5 2935/4885SMYD3 3568/4885HTR1A 4317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.